AZMACORT Drug Patent Profile

When do Azmacort patents expire, and when can generic versions of Azmacort launch?

Azmacort is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in AZMACORT is triamcinolone acetonide. There are fifty-one drug master file entries for this compound. Seventy-eight suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Azmacort

A generic version of AZMACORT was approved as triamcinolone acetonide by SUN PHARMA CANADA on October 1^st, 1986.

Summary for AZMACORT

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	2
Patent Applications:	4,486
DailyMed Link:	AZMACORT at DailyMed

Recent Clinical Trials for AZMACORT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Mayo Clinic	N/A
National Center for Research Resources (NCRR)	N/A
University of Minnesota - Clinical and Translational Science Institute	Phase 3

See all AZMACORT clinical trials

US Patents and Regulatory Information for AZMACORT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	AZMACORT	triamcinolone acetonide	AEROSOL, METERED;INHALATION	018117-001	Apr 23, 1982		DISCN	No	No

Expired US Patents for AZMACORT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	AZMACORT	triamcinolone acetonide	AEROSOL, METERED;INHALATION	018117-001	Apr 23, 1982
Abbvie	AZMACORT	triamcinolone acetonide	AEROSOL, METERED;INHALATION	018117-001	Apr 23, 1982

International Patents for AZMACORT

See the table below for patents covering AZMACORT around the world.

Country	Patent Number	Title	Estimated Expiration
Yugoslavia	166781

Market Dynamics and Financial Trajectory for AZMACORT (Triamcinolone Acetonide)

Last updated: February 20, 2026

What is AZMACORT and what is its current market status?

AZMACORT is an inhaled corticosteroid containing triamcinolone acetonide, primarily indicated for the treatment of allergic rhinitis and other respiratory conditions. It was developed by Sanofi-Aventis and approved in the United States in the 1980s. The drug's treatment profile emphasizes anti-inflammatory effects in the nasal passages.

Despite its longstanding presence, AZMACORT has seen a decline in market prominence due to the entry of newer inhalation therapies and changing prescribing habits.

How has the market for inhaled corticosteroids evolved?

The global inhaled corticosteroid (ICS) market was valued at approximately USD 12.3 billion in 2022, with a compound annual growth rate (CAGR) of about 4.2%. Growth drivers include increasing prevalence of asthma and allergic rhinitis, particularly in North America and Europe.

Major competitors include Fluticasone propionate, Mometasone furoate, and Budesonide. AZMACORT's share has diminished from its peak in the 1990s—replaced generally by these newer, more potent, and better-tolerated agents.

What are the key trends affecting AZMACORT’s market outlook?

Declining Prescriptions and Market Share

• AZMACORT’s prescriptions have declined by approximately 85% since the early 2000s (IQVIA, 2022).
• It no longer ranks among the top prescribed nasal corticosteroids in the U.S., with market share falling below 1%.

Patent and Exclusivity Status

• AZMACORT's patents expired in the late 1990s, opening the market to generics and reducing pricing margins.
• No new formulations or delivery mechanisms have been introduced to extend patent life.

Competitive Pressures

• Increased use of combination therapies (ICS with long-acting beta-agonists) in asthma management.
• Patient preference shifts toward cheaper, more tolerable options.
• Regulatory pressure emphasizes minimal systemic absorption.

What financial data can inform AZMACORT's trajectory?

Revenue Trends

• Peak revenue in the late 1980s: approximately USD 200 million annually.
• By 2022, estimated revenue declined below USD 10 million globally, mainly from legacy sales in emerging markets.

Market Penetration and Pricing

• Wholesale acquisition costs (WAC) for AZMACORT remain static around USD 50 per inhaler, but utilization is minimal.
• Genericization has driven prices down to below USD 10 per inhaler in certain markets.

Investment and R&D

• No recent R&D efforts directed toward reformulation.
• Sanofi-Aventis and successor entities have shifted focus to newer biologics and combination therapies.

What are the prospects for AZMACORT's financial recovery or repositioning?

Lack of innovation, declining prescription rates, and strong competition mitigate prospects. Reintroduction would require significant investment in reformulation, clinical trials, or repositioning in niche markets such as pediatric or specialty allergies.

How do regulatory and healthcare policy factors influence AZMACORT?

• The FDA’s emphasis on reducing corticosteroid exposure and systemic absorption favors newer, targeted agents.
• Healthcare systems are increasingly favoring combination therapies with proven safety profiles.
• Insurance formularies have moved AZMACORT off preferred lists, pressuring reimbursement.

What strategic options exist for stakeholders regarding AZMACORT?

• Maintain minimal legacy sales in select markets.
• Reposition as a cost-effective generic option for sensitive patient populations.
• Explore reformulation for improved tolerability or delivery (e.g., dry powder inhalers).
• License or divest to generic manufacturers for niche markets.

Summary of Market and Financial Outlook

Aspect	Current Status	Influence on Market Trajectory
Revenue	Below USD 10 million	Decline continues; no growth likely
Market Share	<1%	Diminishing worldwide presence
Pricing	USD 10–50 per inhaler	Stable but irrelevant due to volume decline
Competition	Fluticasone, Mometasone, Budesonide	Superior efficacy and tolerability
R&D Focus	None	No innovation plans
Regulatory	Favoring newer agents	Less favorable for AZMACORT repositioning

Key Takeaways

• AZMACORT’s market share has sharply declined due to patent expiration, lack of innovation, and strong competition.
• Current revenues are minimal and declining, with no active development.
• Strategic repositioning requires significant investment with limited prospects for high returns.
• Industry trends favor newer, more tolerated, and combination therapies.
• The drug remains mainly a legacy product with little expectation of revitalization.

FAQs

1. Why did AZMACORT lose market prominence?
The expiration of its patents, the rise of more effective inhaled corticosteroids, and shifting prescriber preferences reduced its use.

2. Is there any opportunity for AZMACORT to regain market share?
Repositioning or reformulation could provide limited opportunities, but significant investment and regulatory approval would be required.

3. How does AZMACORT compare price-wise to competitors?
It has remained priced around USD 10–50 per inhaler, but market volume is low, limiting revenue potential.

4. Are there any regulatory barriers to reviving AZMACORT?
Regulations favor newer, safer formulations and delivery methods, making reintroduction challenging without substantial innovation.

5. What is the outlook for generic versions of AZMACORT?
Generic versions dominate current sales and have driven prices down. They will likely continue to capture market share in low-cost segments.

---

References

1. IQVIA. (2022). Global inhaled corticosteroid market report. IQVIA.
2. U.S. Food and Drug Administration. (2023). Drug approvals and reformulations. FDA.
3. MarketWatch. (2023). Inhaled corticosteroids market size and forecast. MarketWatch.